ML-385 increased anticancer activity of doxorubicin in non-small cell lung cancer (NSCLC) cells with constitutive activation of NRF2 due to KEAP1 homozygous point mutations [25]. Here, NFE2L2 is linked to non-small cell lung carcinoma.